Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Ekaterina V Starostina"'
Autor:
Galina V. Kochneva, Gleb A. Kudrov, Sergei S. Zainutdinov, Irina S. Shulgina, Andrei V. Shipovalov, Anna V. Zaykovskaya, Mariya B. Borgoyakova, Ekaterina V. Starostina, Sergei A. Bodnev, Galina F. Sivolobova, Antonina A. Grazhdantseva, Daria I. Ivkina, Alexey M. Zadorozhny, Larisa I. Karpenko, Oleg V. P’yankov
Publikováno v:
Vaccines, Vol 12, Iss 7, p 783 (2024)
The mouse paramyxovirus Sendai, which is capable of limited replication in human bronchial epithelial cells without causing disease, is well suited for the development of vector-based intranasal vaccines against respiratory infections, including SARS
Externí odkaz:
https://doaj.org/article/c07e7ed33441488e9b4c13fcca6b336e
Autor:
Victoria R. Litvinova, Andrey P. Rudometov, Nadezhda B. Rudometova, Denis N. Kisakov, Mariya B. Borgoyakova, Lyubov A. Kisakova, Ekaterina V. Starostina, Anastasia A. Fando, Vladimir A. Yakovlev, Elena V. Tigeeva, Ksenia I. Ivanova, Andrei S. Gudymo, Tatiana N. Ilyicheva, Vasiliy Yu. Marchenko, Artemiy A. Sergeev, Alexander A. Ilyichev, Larisa I. Karpenko
Publikováno v:
Vaccines, Vol 12, Iss 5, p 538 (2024)
The development of a safe and effective vaccine against avian influenza A virus (AIV) H5N8 is relevant due to the widespread distribution of this virus in the bird population and the existing potential risk of human infection, which can lead to signi
Externí odkaz:
https://doaj.org/article/d93f756465fa44dca5a5e0190483f636
Autor:
Ekaterina A. Volosnikova, Iuliia A. Merkuleva, Tatiana I. Esina, Dmitry N. Shcherbakov, Mariya B. Borgoyakova, Anastasiya A. Isaeva, Valentina S. Nesmeyanova, Natalia V. Volkova, Svetlana V. Belenkaya, Anna V. Zaykovskaya, Oleg V. Pyankov, Ekaterina V. Starostina, Alexey M. Zadorozhny, Boris N. Zaitsev, Larisa I. Karpenko, Alexander A. Ilyichev, Elena D. Danilenko
Publikováno v:
Vaccines, Vol 11, Iss 4, p 808 (2023)
Despite the rapid development and approval of several COVID vaccines based on the full-length spike protein, there is a need for safe, potent, and high-volume vaccines. Considering the predominance of the production of neutralizing antibodies targeti
Externí odkaz:
https://doaj.org/article/f1e47c9a247e478f964607cf1e5745a2
Autor:
Sergei N. Shchelkunov, Stanislav N. Yakubitskiy, Alexander A. Sergeev, Ekaterina V. Starostina, Ksenia A. Titova, Stepan A. Pyankov, Galina A. Shchelkunova, Mariya B. Borgoyakova, Alexey M. Zadorozhny, Lyubov A. Orlova, Denis N. Kisakov, Larisa I. Karpenko
Publikováno v:
Viruses, Vol 14, Iss 7, p 1453 (2022)
The conventional live smallpox vaccine based on the vaccinia virus (VACV) cannot be widely used today because it is highly reactogenic. Therefore, there is a demand for designing VACV variants possessing enhanced immunogenicity, making it possible to
Externí odkaz:
https://doaj.org/article/7c9855202119445588ad2769503afd31
Autor:
Sergei N. Shchelkunov, Aleksander A. Sergeev, Ksenia A. Titova, Stepan A. Pyankov, Ekaterina V. Starostina, Maria B. Borgoyakova, Lubov A. Kisakova, Denis N. Kisakov, Larisa I. Karpenko, Stanislav N. Yakubitskiy
Publikováno v:
Acta Naturae. 14:111-118
The spread of the monkeypox virus infection among humans in many countries outside of Africa, which started in 2022, is now drawing the attention of the medical and scientific communities to the fact that immunization against this infection is sorely
Autor:
Mariya B. Borgoyakova, Larisa I. Karpenko, Andrey P. Rudometov, Ekaterina A. Volosnikova, Iuliia A. Merkuleva, Ekaterina V. Starostina, Alexey M. Zadorozhny, Anastasiya A. Isaeva, Valentina S. Nesmeyanova, Daniil V. Shanshin, Konstantin O. Baranov, Natalya V. Volkova, Boris N. Zaitsev, Lyubov A. Orlova, Anna V. Zaykovskaya, Oleg V. Pyankov, Elena D. Danilenko, Sergei I. Bazhan, Dmitry N. Shcherbakov, Alexander V. Taranin, Alexander A. Ilyichev
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 4, p 2188 (2022)
Despite the fact that a range of vaccines against COVID-19 have already been created and are used for mass vaccination, the development of effective, safe, technological, and affordable vaccines continues. We have designed a vaccine that combines the
Externí odkaz:
https://doaj.org/article/4d510ffb1ac04a2aa2a3264a0aa2c237
Publikováno v:
Medical academic journal. 2:177-181
BACKGROUND: One approach that makes it possible to create vaccines relatively quickly and inexpensively is the creation of DNA vaccine constructs. They are of particular interest for the prevention of COVID-19, as they induce both types of immune res
Autor:
Denis N. Kisakov, Lyubov A. Orlova, Сергей V. Sharabrin, Andrey P. Rudometov, Maria B. Borgoyakova, Ekaterina V. Starostina, Larisa I. Karpenko, Alexander A. Ilyichev
Publikováno v:
Medical academic journal. 2:191-196
BACKGROUND: Nucleic acid-based prevention tools provide a promising platform for developing vaccines, including those against COVID-19. Previously, we developed the pVAXrbd DNA vaccine encoding the receptor-binding domain (RBD) of SARS-CoV-2, which,
Autor:
Mariya B. Borgoyakova, Larisa I. Karpenko, Ekaterina V. Starostina, Ekaterina A. Volosnikova, Alexey M. Zadorozhny, Lyubov A. Orlova, Alexander A. Ilyichev
Publikováno v:
Russian Journal of Immunology. 25:131-138
Massive vaccination against SARS-CoV-2 appears to be one of the most important steps towards solving the problem of the COVID-19 pandemic, which threatened the lives of millions of people over two and a half years. To create anti-COVID-19 vaccines, b
Autor:
Sergei N. Shchelkunov, Alexander A. Sergeev, Stanislav N. Yakubitskiy, Ksenia A. Titova, Stepan A. Pyankov, Irina V. Kolosova, Ekaterina V. Starostina, Mariya B. Borgoyakova, Alexey M. Zadorozhny, Denis N. Kisakov, Irina S. Shulgina, Larisa I. Karpenko
Publikováno v:
Viruses, Vol 13, Iss 8, p 1631 (2021)
Mass vaccination has played a critical role in the global eradication of smallpox. Various vaccinia virus (VACV) strains, whose origin has not been clearly documented in most cases, have been used as live vaccines in different countries. These VACV s
Externí odkaz:
https://doaj.org/article/9724a2bc6d794a6287d7840378ce7ea5